Life Molecular Imaging and PharmaLogic Holdings have inked a partnership and licensing agreement to provide and distribute the imaging agent Neuraceq from PharmaLogic's radiopharmaceutical manufacturing site near Denver, CO.
Neuraceq is a diagnostic agent cleared by the U.S. Food and Drug Administration (FDA) for PET imaging of the brain. It detects beta-amyloid plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other forms of cognitive decline. It is also an imaging biomarker for the characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases, according to the firms.
The companies made the first doses of the agent available on August 20.
